Brolucizumab’s safety under review
- Posted on: Feb 26 2020
- Leave a response
Novartis has launched a safety review of their new anti-VEGF agent brolucizumab (Beovu) following reports of possible unintended side effects after the drug was approved last October.
Source: AAO
Posted in: Uncategorized
